Collaborations with the FDA
FDA Clinical Research Diversity Partnership
To promote scientific progress and diversity in clinical research, Yale School of Medicine and the U.S. Food and Drug Administration Office of Minority Health and Health Equity (OMHHE) have entered in to a formal Memorandum of Understanding (MOU) and agreed to collaborate on a range of far-reaching science-based initiatives. Through trainings, fellowships, internships, research, and education, the agreement will foster the exchange of scientific information between the institutions and improve human health.
Initiative under the MOU include:
- Collaborations to cultivate and advance the Yale Cultural Ambassadors Program and the engagement of community partners to increase participation of diverse and historically under represented or underserved populations in clinical research.
- Advancing education and participation of diversity of the health professional and scientific workforce
- Advancing student education and matriculation into the health and biomedical science professions.
- Opportunities for FDA staff to serve as adjunct faculty or on advisory boards;
- Opportunities to convene joint meetings for education and research;
- Opportunities for Yale students, trainees, and faculty training in the regulatory science pathways;
- Research and evaluation collaborations;
- Cooperative international initiatives; and
- Accessing unique facilities and equipment for scientific endeavors.
For More Information
Tesheia H. Johnson, MBA, MHS
Deputy Director and Chief Operations Officer for the Yale Center for Clinical Investigation
Director of Clinical Research for Yale School of Medicine
Past Events and News
FDA Office of Minority Health and Health Equity (OMHHE)
The FDA Office of Minority Health and Health Equity (OMHHE) serves to promote and protect the health of diverse populations through research and communication of science that addresses health disparities.
We aim to:
- increase the amount of clinical trial data available on racial and ethnic minorities; improve the data quality to determine how minorities react to medical products; and increase transparency and access to available data
- strengthen FDA’s ability to respond to minority health concerns and
- promote health and safety communication to minority populations who often experience low health literacy and/or speak English as a second language.